BCR-ABL Quantitative Test | Accurate Monitoring for Leukemia Detection

Description

BCR / ABL – Quantitative Lab Test

The BCR / ABL – Quantitative test is a specialized diagnostic tool designed to detect and measure the BCR-ABL fusion gene, a genetic abnormality commonly associated with certain types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This test plays a critical role in diagnosing, monitoring, and managing these conditions, helping healthcare providers assess disease progression and treatment effectiveness.

### Why You Need This Test
The BCR / ABL – Quantitative test is essential for individuals suspected of having leukemia or those undergoing treatment for CML or ALL. This test measures the levels of the BCR-ABL fusion gene in the blood, providing valuable insights into the presence and activity of the disease. It is particularly important for monitoring treatment response, as decreasing levels of the BCR-ABL gene indicate effective therapy. Early detection and regular monitoring through this test can significantly improve outcomes by enabling timely adjustments to treatment plans.

### Symptoms That Indicate This Test
You may need the BCR / ABL – Quantitative test if you experience symptoms or conditions such as:
– Persistent fatigue or weakness
– Unexplained weight loss
– Night sweats
– Fever without an apparent cause
– Enlarged spleen or abdominal discomfort
– Easy bruising or bleeding
– Frequent infections
– Abnormal blood counts detected during routine testing

These symptoms are often associated with leukemia and warrant further investigation through this diagnostic test.

### Natural Production
The BCR-ABL fusion gene is not naturally produced by the body. It results from a genetic mutation where parts of the BCR gene on chromosome 22 and the ABL gene on chromosome 9 fuse together, forming what is known as the Philadelphia chromosome. This abnormal gene produces a protein that promotes uncontrolled cell growth, leading to leukemia. Factors such as genetic predisposition or exposure to certain environmental triggers may influence the development of this mutation. The BCR / ABL – Quantitative test is specifically designed to detect and measure this abnormality.

### What Happens If Untreated
If abnormal levels of the BCR-ABL gene are left untreated, the condition can progress rapidly, leading to severe health complications. In cases of CML, untreated disease can advance from a chronic phase to an accelerated or blast phase, where it becomes more aggressive and harder to treat. Similarly, untreated ALL can lead to widespread organ damage, infections, and life-threatening complications. Early detection and ongoing monitoring through the BCR / ABL – Quantitative test are crucial for preventing disease progression and improving survival rates.

### How to Prepare for the Test
Preparation for the BCR / ABL – Quantitative test is straightforward. No fasting or special dietary restrictions are required. However, it is important to inform your healthcare provider about any medications or supplements you are taking, as these may influence test results. Follow any specific instructions provided by your doctor or testing facility to ensure accurate results.

### Test Overview
– Sample Type: Whole Blood
– Methodology: Real-time PCR (Polymerase Chain Reaction)
– Turnaround Time (TAT): 8-10 Days

This test uses advanced real-time PCR technology to detect and quantify the BCR-ABL fusion gene with high precision. A blood sample is collected and analyzed in a specialized laboratory, with results typically available within 8-10 days.

Take control of your health today by scheduling the BCR / ABL – Quantitative test. Whether you’re seeking a diagnosis, monitoring treatment progress, or ensuring long-term disease management, this test provides the critical insights you need. Don’t wait—book your lab test online now

Category: Molecular